[Selective effectiveness of galactose-containing liposome IL-2 on liver lymphocytes].
We have performed immunochemical intraarterial infusion immunochemotherapy containing IL-2, mitomycin C and 5-FU as the main active ingredient for metastatic liver tumor and obtained favorable results. However, we are obliged to perform intra-hepatic arterial infusion once or twice a week, because of the short half-life of IL-2. Thus, we are using a drug delivery system to activate lymphocytes of the liver. We noticed many galactose-receptors in the liver and prepared galactose-containing liposome preparations using various carriers/bases. As a result, galactose-containing liposome preparations showed the highest accumulation and the highest localized enhancing effect on the antitumor activity of lymphocytes in the liver sites.
Nakamura
K
K
Dept. of Surgery I, Kinki University School of Medicine.
Okuno
K
K
Hirohata
T
T
Shigeoka
H
H
Jinnai
H
H
Yasutomi
M
M
D000818:Animals; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005690:Galactose / Q000008:administration & dosage*; D007261:Infusions, Intra-Arterial; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008081:Liposomes; D008099:Liver / Q000166:cytology*; D008113:Liver Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D011956:Receptors, Cell Surface / Q000502:physiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics; D013601:T-Lymphocytes / Q000276:immunology*
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D007376:Interleukin-2; D008081:Liposomes; D011956:Receptors, Cell Surface; D011994:Recombinant Proteins; C039707:galactose receptor; D005690:Galactose